Category - Developments

Developments

Zenabis to supply cannabis extracts for PAX Labs’ Era vaporizer pods

Zenabis Global (TSX:ZENA) has agreed to supply cannabis extracts for PAX Era pods, which are designed for use with PAX Labs’ Era vaporizer device. Under the accord, Zenabis will supply cannabis extracts in the form...

September 30, 2019

Developments

Cheryl Reicin, renowned Canadian corporate lawyer, recognized at LMG Life Sciences awards

Cheryl Reicin, partner at Torys, was named Canada’s financial and corporate attorney of the year at the seventh annual LMG Life Sciences awards. Ms. Reicin is the practice leader of Torys’ life science group...

September 27, 2019

Developments

IntelGenx resubmits acute migraine NDA for RIZAPORT with FDA

IntelGenx (TSXV:IGX; OTCQX:IGXT) resubmitted its 505(b)(2) new drug application for RIZAPORT VersaFilM for the treatment of acute migraines to the FDA. “Over the past several months, we have been working diligently to...

September 27, 2019

Developments

Precipio points to completed validation studies of IV-Cell and HemeScreen

Several large laboratories have successfully completed validation studies to test Precipio’s (NASDAQ:PRPO) IV-Cell cytogenetics media product, as well as its HemeScreen assay, and are proceeding towards placing orders...

September 26, 2019

Developments

Cortexyme begins European screening for Phase 2/3 Alzheimer’s disease trial

Cortexyme (NASDAQ:CRTX) began screening patients in Europe for its international Phase 2/3 trial, called GAIN, to evaluate COR388 in patients with mild-to-moderate Alzheimer’s disease (AD). The company has been...

September 26, 2019

Developments

Marinus Pharma reports positive topline data from Phase 2 epileptic seizure trial

Marinus Pharmaceuticals (NASDAQ:MRNS) reported positive topline results from its Phase 2 trial of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE). Status epilepticus is a prolonged...

September 26, 2019

Developments

Imagin Medical has positive FDA meeting about i/Blue regulatory pathway

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) recently met with the FDA to discuss its premarket approval regulatory pathway for marketing authorization of its i/Blue Imaging System. Based...

September 26, 2019

Developments

Urogen Pharma reports data from two urinary tract cancer trials

UroGen Pharma (NASDAQ:URGN) reported results from its Phase 3 and Phase 2b trials of its mitomycin gel in patients with low-grade upper tract urothelial cancer (UTUC) and intermediate risk low-grade non-muscle invasive...

September 25, 2019

Developments

Achillion gets FDA breakthrough therapy designation for danicopan

Achillion Pharmaceuticals’ (NASDAQ:ACHN) danicopan received FDA breakthrough therapy designation for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). In PNH, the complement system destroys red blood cells in...

September 25, 2019

Developments

Salarius achieves dose-escalation milestones in sarcoma and solid tumor trials

The Safety Review Committees overseeing Salarius Pharmaceuticals’ (NASDAQ:SLRX) Phase 1/2 clinical study of Seclidemstat in Ewing sarcoma and the Phase 1 study of Seclidemstat in patients with advanced solid tumors...

September 25, 2019

Category - Developments

Zenabis to supply cannabis extracts for PAX Labs’ Era vaporizer pods

Cheryl Reicin, renowned Canadian corporate lawyer, recognized at LMG Life Sciences awards

IntelGenx resubmits acute migraine NDA for RIZAPORT with FDA

Precipio points to completed validation studies of IV-Cell and HemeScreen

Cortexyme begins European screening for Phase 2/3 Alzheimer’s disease trial

Marinus Pharma reports positive topline data from Phase 2 epileptic seizure trial

Imagin Medical has positive FDA meeting about i/Blue regulatory pathway

Urogen Pharma reports data from two urinary tract cancer trials

Achillion gets FDA breakthrough therapy designation for danicopan

Salarius achieves dose-escalation milestones in sarcoma and solid tumor trials

General

More